Treatment
Combination therapy clinical trials
We’re tracking 894 recruiting studies that include Combination therapy, each written for real people, not researchers, below.
Recruiting studies
- NCT07130240RecruitingPhase 2
Ivonescimab with chemo before surgery for cervical cancer
This trial tests adding a new drug called Ivonescimab to standard chemotherapy (paclitaxel and cisplatin) given before a hysterectomy in women with cervical cancer stage IB2 or IIA1 (tumor size 2-4 cm). The goal is to see if this combination improves outcomes compared to chemo alone.
ShanghaiAges 18–75 - NCT06766578RecruitingPhase 2
Low-dose radiation plus immunotherapy and chemo before gastric cancer surgery
This trial tests a new combination of low-dose radiation, an immunotherapy drug (tirelizumab), and chemotherapy (SOX) given before surgery for locally advanced gastric or gastroesophageal junction cancer. The goal is to see if this approach can shrink tumors more effectively.
Jinan, ShandongAges 18–75 - NCT06256406Recruiting
Comfort, kangaroo care, and music therapy for NICU newborns
This trial tests whether a comfortable environment, kangaroo care (skin-to-skin contact), and music therapy can help newborns in the neonatal intensive care unit (NICU). It aims to see if these gentle approaches improve their well-being.
Catania, SicilyAges birth–3 years - NCT07034326RecruitingPhase 2/Phase 3
Acupuncture plus immunotherapy after lung cancer surgery
This trial explores whether adding electroacupuncture (a gentle needle treatment with mild electric pulses) to standard immunotherapy after lung cancer surgery can help prevent the cancer from coming back. It is designed for people with early-stage non-small cell lung cancer who have already had chemotherapy.
TianjinAges 18–80 - NCT06091423RecruitingPhase 2
XELOX plus fruquintinib and sintilimab for stomach cancer with liver or lymph node spread
This trial tests a combination of chemotherapy (XELOX), a targeted therapy (fruquintinib), and an immunotherapy (sintilimab) to shrink stomach cancer that has spread only to the liver or retroperitoneal lymph nodes. The goal is to make the cancer removable by surgery.
NanjinAges 18–75 - NCT06841679RecruitingPhase 2/Phase 3
Testing utidelone plus chemo for untreated stomach cancer
This trial tests a new capsule (utidelone) combined with standard chemotherapy as a first treatment for advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. It aims to see if this combination works better than current options.
Hialeah, FloridaAges 18 years+ - NCT06514898RecruitingPhase 1
Personalized cell therapy for recurrent medulloblastoma
This trial tests a combination of personalized immune cells, vaccines, stem cells, and an immunotherapy drug (pembrolizumab) for children and young adults whose medulloblastoma has come back or grown. The goal is to help the immune system fight the cancer more effectively.
Washington D.C., District of ColumbiaAges 4–30 - NCT05837806RecruitingPhase 2
Tislelizumab and disitamab as pre-surgery treatment for HER2 UTUC
This trial tests whether giving tislelizumab plus disitamab vedotin before surgery (neoadjuvant therapy) can improve outcomes for people with HER2-positive, high-risk upper tract urothelial cancer. It also looks at the treatment’s safety and helps doctors learn if certain tumor features predict response.
TianjinAges 18 years+ - NCT06714708RecruitingPhase 2
Low-dose radiation with immunotherapy and chemo before surgery for lung cancer
This trial tests a combination of low-dose radiation, an immunotherapy drug called sintilimab, and standard chemotherapy before surgery for stage II–III non-small cell lung cancer (NSCLC). The goal is to see if this approach can shrink tumors and improve outcomes for patients who are candidates for surgery.
Hefei, AnhuiAges 18 years+ - NCT06904014RecruitingPhase 2
Testing a new drug combo before surgery for liver cancer
This trial tests if combining three therapies (sintilimab, lenvatinib, and HAIC) before surgery can help shrink liver tumors that are on the borderline of being removable. It's for people whose cancer has spread into nearby blood vessels but not to other organs.
Jinan, ShandongAges 18–70 - NCT06192797RecruitingPhase 2
Combination therapy for unresectable bile duct cancer
This trial tests a combination of three treatments—a liver-directed chemotherapy infusion (HAIC), a targeted therapy pill (lenvatinib), and an immunotherapy (pucotenlimab)—to try to shrink bile duct cancers that cannot be surgically removed. The goal is to make the cancer surgically removable or to control it for as long as possible.
Wuhan, HubeiAges 18 years+ - NCT03538899RecruitingPhase 1/Phase 2
Gene therapy for children with an Artemis SCID immune problem
This early-phase study tests an “autologous” gene therapy, meaning they use the child’s own cells, adjusted with a working gene, to help restore immune function. It is for babies and children with Artemis-deficient SCID, aiming to improve T-cell immunity and reduce the need for lifelong infection risk management.
San Francisco, CaliforniaAges 2 months+ - NCT05713994Recruiting
Liver cancer treatments together for unresectable liver tumors
This trial tests a combined treatment plan—chemo delivered to the liver, targeted therapy, anti-VEGF therapy, and immunotherapy—to control unresectable hepatocellular carcinoma (HCC). It may help shrink tumors or slow progression when surgery isn’t possible.
Quanzhou, FujianAges 18 years+ - NCT05717738Recruiting
Immunotherapy plus targeted drugs after TACE for liver cancer
This trial tests a combination of blood-vessel–targeting medicine and immunotherapy after a liver-directed treatment called TACE for advanced hepatocellular carcinoma (HCC). It aims to control tumor growth when surgery or ablation isn’t suitable, and to see if this “conversion therapy” helps patients do better than standard pathways.
Quanzhou, FujianAges 18 years+ - NCT05999149RecruitingPhase 3
Famitinib plus chemo and immunotherapy before breast cancer surgery
This trial tests whether adding a targeted therapy pill (famitinib) to standard chemo plus an immunotherapy (camrelizumab) can shrink triple negative breast cancer before surgery. It may help people with earlier-stage disease who have not had certain prior treatments.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06081673RecruitingPhase 2
Penpulimab plus chemo before and after surgery for head and neck cancer
This trial tests a combination of penpulimab (an immunotherapy drug) and chemotherapy before and after surgery for head and neck cancer. The goal is to see if this approach can improve treatment outcomes for people with resectable (removable by surgery) cancers.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06105099Recruiting
Speech therapy for children with cleft palate
This study tests a special speech therapy program for children with a cleft palate who have speech errors. The therapy focuses on improving speech sounds and seeing if the improvements last over time.
GhentAges 4–12 - NCT06496373RecruitingEarly Phase 1
mRNA vaccine plus immunotherapy after pancreatic cancer surgery
This trial tests a personalized mRNA vaccine combined with an immunotherapy drug (PD-1 inhibitor) to prevent pancreatic cancer from returning after surgery. It is for patients whose tumors have specific genetic features and who cannot have standard chemotherapy.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06509009RecruitingPhase 2
Nimotuzumab and TGP for first-line recurrent / metastatic nasopharyngeal cancer
This trial tests a combination of two drugs—nimotuzumab (a targeted therapy) and TGP (a chemotherapy)—as a first treatment for people whose nasopharyngeal cancer has returned or spread. The goal is to see if this combination can shrink tumors and help patients live longer.
Beijing, Beijing MunicipalityAges 18–75 - NCT06516445RecruitingPhase 2
Short radiation plus targeted drugs before surgery for rectal cancer
This trial tests a new combination of treatments before surgery for locally advanced rectal cancer. You would receive short-course radiation, then an immunotherapy drug (camrelizumab) plus a PARP inhibitor (fluzoparib) and chemotherapy, to shrink the tumor and make surgery more successful.
Wuhan, HubeiAges 18–75 - NCT06838910RecruitingPhase 2
Tislelizumab and anlotinib for thymus cancer after first treatment
This study tests a combination of two drugs (tislelizumab and anlotinib) as a second treatment option for people with thymoma or thymic carcinoma whose cancer has worsened after first-line therapy. It aims to see if this combination can control the tumor and improve outcomes.
Nanjing, JiangsuAges 18–75 - NCT06878222RecruitingPhase 2
Testing an immunotherapy combo before surgery for cervical cancer
This trial tests whether combining two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemotherapy (paclitaxel and cisplatin) before surgery can help shrink cervical cancer. It is for people with certain stages of cervical cancer who are candidates for surgery, including those who want to preserve their fertility.
ShanghaiAges 18–75 - NCT06966934Recruiting
Nasal airway and oxygen for stomach scope in obesity
This trial tests whether a breathing tube placed in the nose (nasopharyngeal airway) combined with high-flow oxygen can improve safety during painless gastroscopy in people with obesity. It may help you breathe better while sedated.
NanjingAges 18 years+ - NCT02885753RecruitingPhase 3
Liver-only metastatic colon cancer trial using targeted chemo
This Phase 3 trial tests different ways to deliver chemotherapy for colon cancer that has spread only to the liver (with limited possible tiny lung spots). It looks at whether the treatment plan improves outcomes compared with another chemotherapy approach, using oxaliplatin and LV5FU2 (with or without irinotecan) plus an added targeted medicine.
BrusselsAges 18 years+
Common questions
- Are there clinical trials studying Combination therapy?
- Yes. Clin2 currently lists 894 recruiting studies that include Combination therapy, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Combination therapy trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Combination therapy an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Combination therapy or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.